Go to deals
Healthcare

ANGLE has completed a placing of new ordinary shares

ANGLE Plc has raised funds to develop the company.

ANGLE, through its subsidiaries, engages in providing products in cancer diagnostics and foetal health. Its main product is the Parsortix cell separation system, which can capture very rare cells from the blood. The company was founded by Andrew D. W. Newland in April 1994 and is headquartered in Guildford, UK.

Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as nominated advisor and joint broker, assisted ANGLE’s management team and shareholders all the way, from the start to the successful completion of the placing. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, seeking new institutional investors, deal structuring, document drafting, liaising with the exchange and the placing pricing and sizing.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Stuart  Andrews

Stuart Andrews

Managing Director

London, United Kingdom
Oaklins Cavendish

Related deals

UAB MediCA klinika has acquired UAB Varpo seimos klinika
Healthcare

UAB MediCA klinika has acquired UAB Varpo seimos klinika

UAB MediCA klinika has acquired UAB Varpo seimos klinika.

Learn more
GBM Resources (ASX:GBZ) has raised US$5.4 million via a placement
Other Industries

GBM Resources (ASX:GBZ) has raised US$5.4 million via a placement

GBM Resources Limited has raised funds to accelerate drilling at the flagship Drummond Basin, along with funding the acquisition of Twin Hills.

Learn more
Alice Queen (ASX:AQX) has raised funds via an institutional placement
Other Industries

Alice Queen (ASX:AQX) has raised funds via an institutional placement

Alice Queen Limited (ASX:AQX) has completed a fundraising. The funds will be used to complete the Horn Island Scoping Study, accelerate exploration activities at Horn Island and support working capital. The placement was significantly oversubscribed and strongly supported by a major shareholder, as well as several existing shareholders and new institutional and sophisticated investors.

Learn more